XP Is Maintained at Equal-Weight by Morgan Stanley
XP Analyst Ratings
Morgan Stanley Maintains XP Inc(XP.US) With Hold Rating, Cuts Target Price to $21
XP Inc. Hold Rating: EPS Adjustments and Price Target Reduction Highlight Cautious Outlook
UBS Maintains XP Inc(XP.US) With Hold Rating, Cuts Target Price to $19
BofA Securities Maintains XP Inc(XP.US) With Buy Rating, Maintains Target Price $25
Morgan Stanley Maintains XP Inc(XP.US) With Hold Rating, Maintains Target Price $24
J.P. Morgan Maintains XP Inc(XP.US) With Buy Rating, Cuts Target Price to $29
XP Analyst Ratings
JP Morgan Maintains Overweight on XP, Raises Price Target to $29
Citi Maintains XP Inc(XP.US) With Buy Rating
Morgan Stanley Maintains XP Inc(XP.US) With Hold Rating, Maintains Target Price $24
XP Inc: Hold Rating Maintained Amid Stable Valuation and Modest Earnings Adjustment
BofA Securities Maintains XP Inc(XP.US) With Buy Rating, Maintains Target Price $25
Morgan Stanley Maintains XP Inc(XP.US) With Hold Rating, Maintains Target Price $24
BofA Securities Maintains XP Inc(XP.US) With Buy Rating, Maintains Target Price $25
Citi Maintains XP Inc(XP.US) With Buy Rating, Maintains Target Price $27
Strong Performance and Promising Outlook Justify Buy Rating for XP Inc.
XP Analyst Ratings
Goldman Sachs Maintains Neutral on XP, Lowers Price Target to $19